StockNews.AI
POAI
StockNews.AI
188 days

Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform

1. Certis Oncology received a patent for its AI/ML platform, CertisAI™. 2. CertisAI™ predicts drug response using gene expression data, improving drug development. 3. The platform aims to democratize access to AI tools in biopharmaceuticals. 4. Patent protection is valid until March 2043, enhancing their competitive edge. 5. The company's efforts may influence advancements in oncology and related fields.

5m saved
Insight
Article

FAQ

Why Bullish?

CertisAI™'s patent enhances competitiveness, similar to how key patents fueled other biotech stocks.

How important is it?

The patent solidifies Certis's market position, potentially impacting POAI positively.

Why Long Term?

Sustained patent protection can lead to lasting market advantages over time.

Related Companies

POAICERTISBMYNVS
February 12, 2025 02:00 PM Eastern Standard Time SAN DIEGO--(BUSINESS WIRE)--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application directed to Certis’s predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™. “The patent marks an important milestone for our company,” said Peter Ellman, President and CEO of Certis. “It substantiates the uniqueness of our proprietary platform and the underlying methods for predicting drug response,” he said. “By offering CertisAI as a service, we are democratizing access to powerful AI/ML tools, leveling the playing field for biopharmaceutical companies that may lack the internal resources required to build proprietary AI into their workflows.” The company launched CertisAI in April 2024 as an extension of its preclinical biopharmaceutical services offering. The platform brings data-driven precision to a variety of early development decisions and provides a virtual environment in which to test and validate hypotheses related to drug efficacy, resistance and synergies. By correlating drug features and drug response with gene expression signatures, CertisAI can optimize preclinical model selection for drug efficacy studies and inform patient enrollment criteria for clinical trials—commonly cited causes of failed development programs. In silico analyses also can inform regulatory strategies, including label expansion and drug repurposing. The patent broadly protects a predictive AI/ML platform that integrates multiple data sets including drug features, gene expression biomarkers, and drug response, as well as the use of patient-derived xenograft (PDX) for model validation. The patent protection is expected to last until March 2043. About CertisAI™ CertisAI™ is a patented predictive artificial intelligence/machine learning (AI/ML) platform developed by Certis Oncology Solutions. It is the first and only commercially available, validated AI/ML platform that predicts therapeutic efficacy by identifying complex gene expression signatures that correlate with drug response. The platform is designed to assist pharmaceutical researchers to develop and clinicians to identify new treatment options for specific cancers based on a tumor’s unique gene expression profile. About Certis Oncology Solutions Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. The company’s product is Oncology Intelligence® — highly predictive therapeutic response data derived from advanced models of cancer. We partner with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials. Since its founding in 2016, Certis has offered personalized functional testing to help inform individual cancer treatment decisions, an approach advocated by cancer researchers and oncology clinicians worldwide. Using our patented artificial intelligence/machine learning platform and more clinically relevant, patient-derived tumor models, we bring certainty to drug development decisions and help secure clear and compelling evidence of drug efficacy. Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in Sorrento Valley, the heart of San Diego’s life sciences industry. For more information about Certis, visit www.certisoncology.com.

Related News